HC Wainwright Has Negative Forecast for ACTU FY2029 Earnings

Actuate Therapeutics, Inc. (NASDAQ:ACTU) – HC Wainwright reduced their FY2029 EPS estimates for shares of Actuate Therapeutics in a note issued to investors on Wednesday, November 19th. HC Wainwright analyst S. Ramakanth now expects that the company will earn $0.08 per share for the year, down from their prior estimate of $0.11. HC Wainwright currently has a “Buy” rating and a $20.00 target price on the stock.

Several other analysts have also weighed in on the stock. B. Riley assumed coverage on Actuate Therapeutics in a research note on Tuesday, August 26th. They issued a “buy” rating and a $20.00 target price for the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Actuate Therapeutics in a research report on Thursday, November 13th. Finally, Wall Street Zen raised shares of Actuate Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, September 20th. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Actuate Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $20.33.

Actuate Therapeutics Price Performance

Shares of Actuate Therapeutics stock traded down $0.20 during midday trading on Thursday, reaching $5.65. The company had a trading volume of 14,043 shares, compared to its average volume of 66,880. The firm has a market cap of $131.31 million, a PE ratio of -6.50 and a beta of -0.23. The stock has a fifty day moving average price of $6.86 and a 200 day moving average price of $7.67. Actuate Therapeutics has a fifty-two week low of $5.47 and a fifty-two week high of $11.99.

Actuate Therapeutics (NASDAQ:ACTU) last issued its quarterly earnings data on Thursday, November 13th. The company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.02.

Hedge Funds Weigh In On Actuate Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Voss Capital LP increased its holdings in Actuate Therapeutics by 101.0% during the 2nd quarter. Voss Capital LP now owns 286,140 shares of the company’s stock valued at $1,748,000 after purchasing an additional 143,759 shares during the period. BIOS Capital Management LP increased its stake in shares of Actuate Therapeutics by 0.9% in the 3rd quarter. BIOS Capital Management LP now owns 10,049,996 shares of the company’s stock worth $67,234,000 after acquiring an additional 84,917 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Actuate Therapeutics by 252.5% in the 2nd quarter. Geode Capital Management LLC now owns 118,050 shares of the company’s stock worth $721,000 after buying an additional 84,561 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Actuate Therapeutics by 19.5% in the third quarter. Vanguard Group Inc. now owns 316,010 shares of the company’s stock worth $2,114,000 after acquiring an additional 51,546 shares during the last quarter. Finally, Gleason Group Inc. purchased a new position in Actuate Therapeutics in the second quarter worth about $116,000.

Actuate Therapeutics Company Profile

Actuate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company’s lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer.